Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10335922 | PMC |
| http://dx.doi.org/10.1038/s41443-022-00595-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Oral drug treatments of erectile dysfunction: a AFU/SFMS systematic review.
Fr J Urol
September 2025
Department of urology, Maison de Santé Protestante de Bordeaux-Bagatelle, Talence, France; Department of urology, HIA Robert-Picqué, Villenave d'Ornon, France.
Objectives: To evaluate the efficacy and safety of oral phosphodiesterase-5 inhibitors (PDE5Is) in the treatment of erectile dysfunction (ED). Additionally, to compare various PDE5Is and assess their suitability for different patient populations.
Evidence Acquisition: A systematic review of literature published from January 1999 to January 2023 was conducted following the PICOS criteria.
Altering the gut microbiome and tumor microenvironment in advanced liver cancer: A phase II study of nivolumab, tadalafil and oral vancomycin in patients with refractory primary hepatocellular carcinoma or liver dominant metastatic cancer from colorectal or pancreatic cancers.
Cancer Lett
August 2025
Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA; Liver Cancer Program, Center for Cancer Research (CCR), National Cancer Institute, National Institutes of Health, Bethesda, MD
A phase II study was conducted in patients with primary hepatocellular carcinoma or liver dominant metastatic cancer from colorectal (CRC) or pancreatic (PDAC) cancers to assess the effect of nivolumab (anti-PD1), oral vancomycin and tadalafil. Patients were treated with 480 mg nivolumab intravenously every 4 weeks, oral 10 mg tadalafil daily and 125 mg vancomycin orally every 6 h days 1-21 of a 28-day cycle. The primary endpoint was best overall response.
View Article and Find Full Text PDFTadalafil Treatment in Patients With Cerebral Small Vessel Disease: The ETLAS-2 Randomized Clinical Trial.
Stroke
July 2025
Neurovascular Research Unit, Department of Neurology, Copenhagen University Hospital-Herlev and Gentofte, Denmark. (J.O., M.B.T., C.K.).
Background: White matter hyperintensities and reduced cerebral blood flow are hallmarks of cerebral small vessel disease (CSVD). We tested the feasibility of daily treatment with the vasoactive drug tadalafil in patients with CSVD and its effects on cognition and imaging markers of CSVD.
Methods: The ETLAS-2 Trial was a randomized, placebo-controlled, double-blind, parallel phase II trial testing 3 months of daily tadalafil 20 mg versus placebo in patients with CSVD and previous stroke or transient ischemic attack.
Presence of Sildenafil and Tadalafil in Herbal Medicinal Products Claimed to Treat Erectile Dysfunction in Nyamagana and Ilemela Districts, Mwanza, Tanzania.
Biomed Res Int
July 2025
Department of Medicinal Chemistry and Pharmacognosy, School of Pharmacy, Catholic University of Health and Allied Sciences, Mwanza, Tanzania.
Herbal products are increasingly utilized for various conditions, including erectile dysfunction (ED), due to their minimal side effects, affordability, and natural properties. Phosphodiesterase type 5 inhibitors (PDE 5is) such as sildenafil citrate, tadalafil, vardenafil hydrochloride, and avanafil are synthetic oral medications approved for ED treatment. However, multiple studies have highlighted the contamination of herbal aphrodisiacs with PDE 5i or their conventional analogs.
View Article and Find Full Text PDFThe effect of tadalafil 5 mg on erection and persistent storage lower urinary tract symptoms after transurethral resection of prostate: a randomized controlled study.
Basic Clin Androl
July 2025
Department of Urology, Faculty of Medicine, Kafrelsheikh University, Kafrelsheikh University Hospital, El-Giesh Street, Kafrelsheikh, 33155, Egypt.
Background: We conducted a double-blind, randomized controlled trial to evaluate the effect of early administration of tadalafil (5 mg once daily) on persistent storage lower urinary tract symptoms (LUTS) and erectile function following transurethral resection of the prostate (TURP). All enrolled patients underwent TURP and were randomly assigned to one of two groups: Group A received tadalafil (5 mg once daily) postoperatively, while Group B received a placebo. Erectile function was assessed using the International Index of Erectile Function-5 (IIEF-5) questionnaire, and LUTS were evaluated using the International Prostate Symptom Score (IPSS).
View Article and Find Full Text PDF